COVID-19: For information related to COVID-19 (formerly referred to as “novel coronavirus"), visit massey.vcu.edu/covid-19

VCU Massey Cancer Center

Menu

Research

Reed and team

VCU technology could upend DNA sequencing for diagnosing certain DNA mutations

Doctors are increasingly using genetic signatures to diagnose diseases and determine the best course of care, but using DNA sequencing and other techniques to detect genomic rearrangements remains costly or limited in capabilities. However, an innovative breakthrough developed by researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Department of Physics promises to diagnose DNA rearrangement mutations at a fraction of the cost with improved accuracy.

Continue reading →

Image of Professor Semi Ryu with kinetic imaging equipment in the background

VCUarts and Massey Cancer Center win Hamilton International Arts in Health Award

Last year, 12 patients in the Supportive Care Clinic at VCU Massey Cancer Center stepped inside a conference room, donned motion sensors and engaged in a facilitated life review, acting out various parts of their lives through a virtual avatar displayed on a projection screen. Recently, the unique collaboration between researchers at VCUarts and Massey’s Palliative Care Program was recognized with a tie for first place in the 2nd Annual Hamilton International Arts in Health Awards from the National Organization for Arts in Health (NOAH).

Continue reading →

Illustration of the COVID-19 Virus

Study shows the experimental drug AR-12 could be a promising COVID-19 treatment

A team of scientists led by Paul Dent, Ph.D., at Virginia Commonwealth University Massey Cancer Center has discovered that an experimental cancer drug called AR-12 inhibits the SARS-CoV-2 virus, the cause of the COVID-19 pandemic, from infecting cells and replicating. Their findings were published online today in the journal Biochemical Pharmacology, and steps are now being taken to develop a clinical trial testing the novel oral treatment at VCU Health.

Continue reading →

Andrew Poklepovic reviewing imaging results on his office computer.

Clinical trial tests whether immunotherapy helps prevent melanoma recurrence

A stage 2 clinical trial testing the use of immunotherapy after surgery to reduce melanoma recurrence is currently underway at VCU Massey Cancer Center. Led by Andrew Poklepovic, M.D., the trial is eligible to any adult melanoma who is about to or recently underwent surgery and has no evidence of metastatic disease.

Continue reading →

Steven Grant, M.D.

Massey researchers first to show that a specific protein inhibitor successfully kills multiple myeloma tumor cells

Cyclin-dependent kinase inhibitor 7 (CDK7) is a protein that regulates cell cycle progression. However, it also plays a key role in controlling transcription of three genes that help tumor cells proliferate and survive in patients with multiple myeloma, a form of plasma cell cancer.

Continue reading →